Search Results Search Sort by RelevanceMost Recent Case and Commentary Aug 2019 How Should Physicians Steward Limited Resources While Ensuring That Patients Can Access Needed Medicines? Pete Croughan and Rebekah E. Gee, MD, MPH Louisiana has a subscription model for hepatitis C treatment, but costly medications challenge states’ capacities to cover patients. AMA J Ethics. 2019;21(8):E630-635. doi: 10.1001/amajethics.2019.630. State of the Art and Science Aug 2019 Evolving Medicaid Coverage Policy and Rebates Jennifer A. Ohn, MPH and Anna Kaltenboeck, MA Ethics questions arise about the usefulness of a system that pegs Medicaid drug spending to net prices negotiated by others in the market. AMA J Ethics. 2019;21(8):E645-653. doi: 10.1001/amajethics.2019.645. Policy Forum Aug 2019 Should a Law Governing the Pharmaceutical Market Be Ethically Examined Based on Its Intent or Its Practical Applications? Jordan M. Warchol, MD, MPH In 1984, Hatch-Waxman tried to balance drug innovation against availability; it was tested in the US Supreme Court in 2013. AMA J Ethics. 2019;21(8):E661-667. doi: 10.1001/amajethics.2019.661. Policy Forum Aug 2019 Why Are Biosimilars Not Living up to Their Promise in the US? Mike Z. Zhai, Ameet Sarpatwari, JD, PhD, and Aaron S. Kesselheim, MD, JD, MPH Overall utilization of the few biosimilars currently available to patients has been limited. AMA J Ethics. 2019;21(8):E668-678. doi: 10.1001/amajethics.2019.668. AMA Code Says Aug 2019 AMA Code of Medical Ethics’ Opinions Related to Prescription Drugs Rachel F. Harbut and Danielle Hahn Chaet, MSB The AMA Code of Medical Ethics offers guidance on stewardship and professionalism. AMA J Ethics. 2019;21(8):E642-644. doi: 10.1001/amajethics.2019.642. State of the Art and Science Aug 2019 Are Medicaid Closed Formularies Unethical? Leah Rand, DPhil and Govind Persad, JD, PhD Closed formularies can be justified when they enable spending on other socially valuable aims, but they can single out poor patients. AMA J Ethics. 2019;21(8):E654-660. doi: 10.1001/amajethics.2019.654. Case and Commentary Sep 2019 What Are Criteria for Considering Technologies’ Uses and Influences in LMICs’ Health Care Infrastructures? Rolvix Patterson and Richard Rohrer, MD Low-resource areas are heterogeneous and changing, so establishing an evidence base for decision making about technology use is an important priority. AMA J Ethics. 2019;21(9):E735-741. doi: 10.1001/amajethics.2019.735. Medicine and Society Sep 2019 Are Patients’ and Communities’ Poverty Exploited to Give Health Professions Students Learning Experiences? Harold W. Baillie, PhD and John F. McGeehan, MD Exploitation can be exacerbated when health professions students’ educational goals are overemphasized relative to patients’ and communities’ needs. AMA J Ethics. 2019;21(9):E801-805. doi: 10.1001/amajethics.2019.801. Medicine and Society Jan 2019 Strategies for Responding to Undocumented Immigrants With Kidney Disease Jonathan J. Suarez, MD, MSCE Regularly scheduled dialysis is not standard of care for most undocumented immigrants in the United States, so preventative care, and advocacy for it, is needed. AMA J Ethics. 2019;21(1):E86-92. doi: 10.1001/amajethics.2019.86. History of Medicine May 2020 What Does the Evolution From Informed Consent to Shared Decision Making Teach Us About Authority in Health Care? James F. Childress, PhD and Marcia Day Childress, PhD Reliance on disclosure rather than understanding has prompted shared decision making and represents an important cultural change in clinical practice. AMA J Ethics. 2020;22(5):E423-429. doi: 10.1001/amajethics.2020.423. Pagination First page « First Previous page ‹ Previous … Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Page 9 Page 10 Page 11 … Next page Next › Last page Last »
Case and Commentary Aug 2019 How Should Physicians Steward Limited Resources While Ensuring That Patients Can Access Needed Medicines? Pete Croughan and Rebekah E. Gee, MD, MPH Louisiana has a subscription model for hepatitis C treatment, but costly medications challenge states’ capacities to cover patients. AMA J Ethics. 2019;21(8):E630-635. doi: 10.1001/amajethics.2019.630.
State of the Art and Science Aug 2019 Evolving Medicaid Coverage Policy and Rebates Jennifer A. Ohn, MPH and Anna Kaltenboeck, MA Ethics questions arise about the usefulness of a system that pegs Medicaid drug spending to net prices negotiated by others in the market. AMA J Ethics. 2019;21(8):E645-653. doi: 10.1001/amajethics.2019.645.
Policy Forum Aug 2019 Should a Law Governing the Pharmaceutical Market Be Ethically Examined Based on Its Intent or Its Practical Applications? Jordan M. Warchol, MD, MPH In 1984, Hatch-Waxman tried to balance drug innovation against availability; it was tested in the US Supreme Court in 2013. AMA J Ethics. 2019;21(8):E661-667. doi: 10.1001/amajethics.2019.661.
Policy Forum Aug 2019 Why Are Biosimilars Not Living up to Their Promise in the US? Mike Z. Zhai, Ameet Sarpatwari, JD, PhD, and Aaron S. Kesselheim, MD, JD, MPH Overall utilization of the few biosimilars currently available to patients has been limited. AMA J Ethics. 2019;21(8):E668-678. doi: 10.1001/amajethics.2019.668.
AMA Code Says Aug 2019 AMA Code of Medical Ethics’ Opinions Related to Prescription Drugs Rachel F. Harbut and Danielle Hahn Chaet, MSB The AMA Code of Medical Ethics offers guidance on stewardship and professionalism. AMA J Ethics. 2019;21(8):E642-644. doi: 10.1001/amajethics.2019.642.
State of the Art and Science Aug 2019 Are Medicaid Closed Formularies Unethical? Leah Rand, DPhil and Govind Persad, JD, PhD Closed formularies can be justified when they enable spending on other socially valuable aims, but they can single out poor patients. AMA J Ethics. 2019;21(8):E654-660. doi: 10.1001/amajethics.2019.654.
Case and Commentary Sep 2019 What Are Criteria for Considering Technologies’ Uses and Influences in LMICs’ Health Care Infrastructures? Rolvix Patterson and Richard Rohrer, MD Low-resource areas are heterogeneous and changing, so establishing an evidence base for decision making about technology use is an important priority. AMA J Ethics. 2019;21(9):E735-741. doi: 10.1001/amajethics.2019.735.
Medicine and Society Sep 2019 Are Patients’ and Communities’ Poverty Exploited to Give Health Professions Students Learning Experiences? Harold W. Baillie, PhD and John F. McGeehan, MD Exploitation can be exacerbated when health professions students’ educational goals are overemphasized relative to patients’ and communities’ needs. AMA J Ethics. 2019;21(9):E801-805. doi: 10.1001/amajethics.2019.801.
Medicine and Society Jan 2019 Strategies for Responding to Undocumented Immigrants With Kidney Disease Jonathan J. Suarez, MD, MSCE Regularly scheduled dialysis is not standard of care for most undocumented immigrants in the United States, so preventative care, and advocacy for it, is needed. AMA J Ethics. 2019;21(1):E86-92. doi: 10.1001/amajethics.2019.86.
History of Medicine May 2020 What Does the Evolution From Informed Consent to Shared Decision Making Teach Us About Authority in Health Care? James F. Childress, PhD and Marcia Day Childress, PhD Reliance on disclosure rather than understanding has prompted shared decision making and represents an important cultural change in clinical practice. AMA J Ethics. 2020;22(5):E423-429. doi: 10.1001/amajethics.2020.423.